These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27530235)

  • 21. Treatment of inflammatory bowel disease with corticosteroids.
    Katz JA
    Gastroenterol Clin North Am; 2004 Jun; 33(2):171-89, vii. PubMed ID: 15177533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials.
    Schreiber A; Brochard S; Rippert P; Fontaine-Carbonnel S; Payan C; Poirot I; Hamroun D; Vuillerot C;
    Dev Med Child Neurol; 2018 Feb; 60(2):185-191. PubMed ID: 28990163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Steroids: friends or foes?].
    Gomollón F; Hinojosa J
    Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():1-2. PubMed ID: 19087856
    [No Abstract]   [Full Text] [Related]  

  • 24. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy.
    Li X; Conklin LS; van den Anker J; Hoffman EP; Clemens PR; Jusko WJ
    J Clin Pharmacol; 2020 Oct; 60(10):1385-1396. PubMed ID: 32434278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-medication with steroids in inflammatory bowel disease.
    Filipe V; Allen PB; Peyrin-Biroulet L
    Dig Liver Dis; 2016 Jan; 48(1):23-6. PubMed ID: 26611334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Systemic corticosteroids in inflammatory bowel disease: are they really effective. What is their real toxicity?].
    Bastida G; Muñoz F
    Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():3-9. PubMed ID: 19087857
    [No Abstract]   [Full Text] [Related]  

  • 27. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.
    King WM; Ruttencutter R; Nagaraja HN; Matkovic V; Landoll J; Hoyle C; Mendell JR; Kissel JT
    Neurology; 2007 May; 68(19):1607-13. PubMed ID: 17485648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corticosteroids.
    Rosen CM
    Pediatr Rev; 2019 Oct; 40(10):546-548. PubMed ID: 31575809
    [No Abstract]   [Full Text] [Related]  

  • 29. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy.
    Kim S; Zhu Y; Romitti PA; Fox DJ; Sheehan DW; Valdez R; Matthews D; Barber BJ;
    Neuromuscul Disord; 2017 Aug; 27(8):730-737. PubMed ID: 28645460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticosteroids in the treatment of gastrointestinal disease.
    Hyams JS
    Curr Opin Pediatr; 2000 Oct; 12(5):451-5. PubMed ID: 11021409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.
    Markham LW; Kinnett K; Wong BL; Woodrow Benson D; Cripe LH
    Neuromuscul Disord; 2008 May; 18(5):365-70. PubMed ID: 18436445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative tolerability of treatments for inflammatory bowel disease.
    Stein RB; Hanauer SB
    Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying evidence of cardio-renal syndrome in patients with Duchenne muscular dystrophy using cystatin C.
    Villa CR; Kaddourah A; Mathew J; Ryan TD; Wong BL; Goldstein SL; Jefferies JL
    Neuromuscul Disord; 2016 Oct; 26(10):637-642. PubMed ID: 27542440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease.
    Leung YP; Kaplan GG; Coward S; Tanyingoh D; Kaplan BJ; Johnston DW; Barkema HW; Ghosh S; Panaccione R; Seow CH; ;
    J Crohns Colitis; 2015 Mar; 9(3):223-30. PubMed ID: 25576754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corticosteroids and Duchenne muscular dystrophy: does earlier treatment really matter?
    McDonald CM; Han JJ; Mah JK; Carter GT
    Muscle Nerve; 2012 Jun; 45(6):777-9. PubMed ID: 22581529
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys.
    Tawalbeh S; Samsel A; Gordish-Dressman H; Hathout Y; Investigators CD; Dang UJ
    J Pers Med; 2020 Oct; 10(4):. PubMed ID: 33053810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of corticotherapy, nutrition, and sleep disorder on quality of life of patients with Duchenne muscular dystrophy.
    Jeronimo G; Nozoe KT; Polesel DN; Moreira GA; Tufik S; Andersen ML
    Nutrition; 2016 Mar; 32(3):391-3. PubMed ID: 26701140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy.
    de Carvalho SC; Matsumura CY; Santo Neto H; Marques MJ
    Cytokine; 2018 Feb; 102():55-61. PubMed ID: 29276972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy.
    Gasparetto M; Guariso G; Pozza LV; Ross A; Heuschkel R; Zilbauer M
    BMC Gastroenterol; 2016 Mar; 16():35. PubMed ID: 26976427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.